BiVictriX secures US patent for flagship therapeutic asset

Cancer treatment developer BiVictriX Therapeutics has secured a significant patent from the United States Patent and Trademark Office (USPTO), it announced on Wednesday, for its flagship therapeutic asset, BVX001.

The AIM-traded company said the patent was part of the broader ‘Therapy’ patent family, which was currently undergoing review in eight different global territories.

It said the issued patent in the US granted comprehensive protection at the antigen level for BVX001.

In technical terms, the US-awarded patent encompassed broad rights for an antibody-based treatment combined with a cytotoxic, or cell-killing, component.

That, the board said, could be an alternative antibody drug conjugate (ADC) therapy or any related therapeutic method.

It said the key feature of the therapy was its ability to target BiVicitriX’s unique ‘Bi-Cygni’ twin antigen fingerprint, labelled CD7 x CD33.

That targeted approach was said to be particularly useful in the treatment of blood cancers that display both CD7 and CD33 markers, such as acute myeloid leukaemia (AML).

It added that the patent safeguards the company's rights across any haematological cancer type that tests positive for those markers, offering an extensive protective umbrella for BiVictriX.

That protection would persist even if alternative therapeutic methods or components were employed - a tactic often used by competitors to design rival treatments.

On the heels of the US patent's approval, which was anticipated following a notice of allowance in July, BiVictriX said it had received an additional notice of allowance from the Japanese Patent Office concerning a related patent.

That patent was expected to be greenlit in Japan in the coming weeks.

BiVictriX disclosed that it was in the process of seeking approval for the patent family in six other global jurisdictions, adding that it anticipated more patent approvals in the coming months.

“I am excited to announce that our first patent has been granted in the United States,” said chief executive officer Tiffany Thorn.

“This patent relates to our broadest patent family, providing robust protection for BVX001 at the antigen level, across multiple cancer types, and acts as a key milestone for the company demonstrating the breadth of patent protection we can achieve with the ‘Bi-Cygni’ approach.

“This patent grant is expected to be the first of many as we continue to prosecute the wider patent family in seven further jurisdictions worldwide, creating a robust patent protected portfolio.”

At 0958 BST, shares in BiVictriX Therapeutics were up 10.15% at 14.32p.

Reporting by Josh White for Sharecast.com.